Q-omics provides the consensus-scored MIR34C profile across patient tissues and cancer cell-line models. MIR34C expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MIR34C is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, MIR34C RNA expression shows 9,003 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, LUSC, and THYM as cancer lineages where MIR34C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR34C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR34C survival associations across molecular data types. MIR34C RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR34C RNA expression–survival associations across cancer types. High MIR34C expression shows unfavorable associations in ACC, KIRC, COAD, DLBC and ESCA, but favorable associations in HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MIR34C RNA expression.
This table summarizes MIR34C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR34C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR34C shows lower tumor expression in LUSC, LUAD, UCEC and PRAD and higher tumor expression in KIRP. The LUSC box plot shows higher MIR34C RNA expression in normal versus tumor tissue (log2 FC = −2.080, t-test p < 0.001).
This table shows molecular features associated with MIR34C in patient tissues and cancer cell lines. In patient samples, MIR34C shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
